We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
Read MoreHide Full Article
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $59.12, marking a +1.23% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.26%. Meanwhile, the Dow experienced a rise of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.48%.
The company's shares have seen an increase of 37.9% over the last month, surpassing the Medical sector's loss of 0.57% and the S&P 500's gain of 2.87%.
The investment community will be paying close attention to the earnings performance of Hims & Hers Health, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be $0.09, reflecting a 50% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $581.61 million, up 44.84% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.6 per share and a revenue of $2.35 billion, signifying shifts of +122.22% and +58.91%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, Hims & Hers Health, Inc. holds a Zacks Rank of #3 (Hold).
Investors should also note Hims & Hers Health, Inc.'s current valuation metrics, including its Forward P/E ratio of 97.64. This valuation marks a premium compared to its industry average Forward P/E of 46.33.
Investors should also note that HIMS has a PEG ratio of 3.94 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Info Systems industry had an average PEG ratio of 3.28 as trading concluded yesterday.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 63, positioning it in the top 26% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $59.12, marking a +1.23% move from the previous day. The stock's change was more than the S&P 500's daily gain of 0.26%. Meanwhile, the Dow experienced a rise of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.48%.
The company's shares have seen an increase of 37.9% over the last month, surpassing the Medical sector's loss of 0.57% and the S&P 500's gain of 2.87%.
The investment community will be paying close attention to the earnings performance of Hims & Hers Health, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be $0.09, reflecting a 50% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $581.61 million, up 44.84% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.6 per share and a revenue of $2.35 billion, signifying shifts of +122.22% and +58.91%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, Hims & Hers Health, Inc. holds a Zacks Rank of #3 (Hold).
Investors should also note Hims & Hers Health, Inc.'s current valuation metrics, including its Forward P/E ratio of 97.64. This valuation marks a premium compared to its industry average Forward P/E of 46.33.
Investors should also note that HIMS has a PEG ratio of 3.94 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Info Systems industry had an average PEG ratio of 3.28 as trading concluded yesterday.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 63, positioning it in the top 26% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.